variety of cancers had been treated with OGX-427 as a single agent in a dose escalation Phase 1 trial. OGX-427 was well tolerated. Declines in circulating tumor cells (CTCs), an emerging metric to assess treatment effect, have been observed at all dose levels. Changes in tumor markers (i.e declines of PSA, CA-125) have also been observed. Reductions in CTCs and tumor markers both suggest single-agent activity.
The abstract represents preliminary data on OGX-427 as a single agent. Updated data will be presented during an oral presentation at ASCO.
The oral presentations are scheduled to be held as shown below at the ASCO Annual Meeting in Orlando, Florida.
Title: Mature results of a randomized phase II study of OGX-011 in
combination with docetaxel/prednisone versus
docetaxel/prednisone in patients with metastatic castration
resistant prostate cancer
Authors: K. N. Chi, S. J. Hotte, E. Yu, D. Tu, B. Eigl, I. Tannock, F.
Saad, S. North, J. Powers, E. Eisenhauer, National Cancer
Institute of Canada Clinical Trials Group
Date: 4:30 p.m. - 4:45 p.m. EDT, Saturday, May 30, 2009
Location: Level 3, Chapin Theatre, W320, Orange County Convention Center
Abstract: # 5012
Title: OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO),
against HSP27: Results of a first-in-human trial
Authors: S. J. Hotte, E. Y. Yu, H. W. Hirte, C. S.Higano, M. Gleave, K.
Date: 2:00 p.m. - 2:15 p.m. EDT, Saturday, May 30, 2009
Location: Level 4, Valencia Room, W415A, Orange County Convention Center
Abstract: # 3506
OGX-011 is designed to inhibit the production of clusterin, a protein that is associated with cancer treatment resistance and is currently being evaluated in Phase 2 clinical trials in prostate, lung
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting2
. OncoGenex Reports First Quarter Financial Results3
. OncoGenex Pharmaceuticals to Release First Quarter Financial Results4
. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer5
. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia6
. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 20097
. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 20098
. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer9
. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference10
. OncoGenex Reports Third Quarter Financial Results11
. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results